Is Enliven Therapeutics (ELVN) a Buy After Its Upsized Offering and Positive Clinical Data

Related Articles

Why Did Medicus Pharma's Stock Crash After Positive Clinical Data

5 months ago

Why is Thermo Fisher Betting Big on Clinical Trial Data

5 months ago

What Does Tandem Diabetes Care's Upsized Convertible Note Offering Mean for Investors

6 months ago

OrbiMed's $39 Million Sale: A Strategic Exit, Not a Bearish Signal, for Enliven Therapeutics

1 months ago

Category

You may also like

Stock News•1 week ago

Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

Enliven Therapeutics (ELVN) received an Outperform rating from William Blair on Tuesday, citing lead candidate ELVN-001's potential to disrupt the chronic myeloid leukemia treatment market.

ELVN

Share

Stock News•2 weeks ago

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics priced an upsized $175M underwritten public offering of 12,962,963 ADSs at $13.50 each, after strong demand. The clinical-stage biotech could use proceeds to fund siRNA pipeline d...

SLN

Share

Stock News•2 weeks ago

Iovance: Stock Soars On Q2 Earnings - Critical Data In Melanoma, NSCLC Due September

Iovance Biotherapeutics' stock rose after Q2 product revenues hit $99M, 10% above guidance, with a net loss of $(47.3M) beating consensus. Key melanoma and NSCLC data are due at ESMO in September, wit...

IOVA

Share

Stock News•1 months ago

Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026?

AtaiBeckley stock rallied in 2026, driven by expectations ahead of key pipeline milestones. The stock's outlook now hinges on upcoming clinical data and execution.

ATAI

Share